Total
0
Shares
Clinuvel Pharmaceuticals (ASX:CUV) - Chief Executive Officer, Philippe Wolgen
Chief Executive Officer, Philippe Wolgen
Source: The Photoprotection Channel
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clinuvel Pharmaceuticals (CUV) is expanding its clinical programme to test Scensse’s ability to repair skin cells damaged by sun exposure
  • This will generate clinical data on the safety and efficacy of Scensse by incorporating patients with rare inherited genetic disorders
  • The programmes will include patients with XP-V and XP-C, which are characterised by high sensitivity to sunlight and a high subsequent susceptibility to associated skin cancers
  • Clinuvel’s chief scientific officer says Scensse’s active ingredient — Afamelanotide — has been shown to protect skin from UV rays and repair photodamage
  • Clinuvel Pharmaceuticals is down 1.50 per cent following the announcement, trading at $28.21 per share

Clinuvel Pharmaceuticals (CUV) is expanding its clinical programme to test Scensse’s ability to repair skin cells damaged by sun exposure.

The drug, which has been approved by Therapeutic Goods Administration, is typically administered to prevent phototoxicity in adult patients with erythropoietic protoporphyria, a rare metabolic disorder.

Having reached an agreement with clinical and academic experts, Clinuvel is set to generate clinical data on the safety and efficacy of Scensse.

More specifically, this latest expansion to Clinuvel’s clinical programme will include patients with the rare inherited disorders XP-V and XP-C, which are characterised by an extreme sensitivity to sunlight and subsequent skin cancers.

According to Clinuvel’s chief scientific officer Dr Dennis Wright, Scensse’s active ingredient — Afamelanotide — has been shown to protect skin from UV rays and repair photodamage.

“XP patients are at extreme risk of cancer – up to 10,000 times that of the general population – due to their inability to repair damage caused by UV and sunlight, known as photodamage,” he explained.

Scensse is said to improve the function of skin cells which incurred such damage and assist cells in repairing DNA through several mechanisms.

“We are now working to confirm this concept with both XP and patients and healthy volunteers,” he commented.

The company has not provided any further information regarding first results this year, pandemic permitting.

Clinuvel Pharmaceuticals is down 1.50 per cent following the announcement, trading at $28.21 per share at 1:22 pm AEDT.

CUV by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.